Abstract
Respiratory viral illnesses are common and can lead to severe outcomes, including hospitalization and death. U.S. trends in respiratory virus activity during July 2025–June 2026 were analyzed using data from six complementary public health surveillance systems. Respiratory syncytial virus (RSV) activity occurred unusually late in most U.S. regions. SARS-CoV-2 circulated nationally with typical bimodal peaks that occurred in August 2025 and January 2026. Annual RSV-associated hospitalization rates (number of hospitalizations per 100,000 persons) were highest among infants aged <12 months (790.2; 95% CI = 757.9–825.3), followed by children aged 12–23 months (611.9; 95% CI = 586.3–639.8) and adults aged ≥75 years (352.1; 95% CI = 309.9–407.7). Annual RSV rates overall and by age group did not exceed those observed during 2022–2025. COVID-19–associated hospitalization rates were highest among adults aged ≥75 years (361.2), infants aged <6 months (173.3), and adults aged 65–74 years (111.4). Newly established 2025–2026 national pediatric mortality surveillance provisionally identified 34 RSV-associated pediatric deaths from 35 reporting jurisdictions and 31 COVID-19–associated pediatric deaths from 43 reporting jurisdictions. RSV sequencing did not identify variant substitutions associated with reduced susceptibility to the available RSV monoclonal antibodies for infants. Most SARS-CoV-2 lineages were JN.1 descendants, but detections of BA.3.2, a highly divergent SARS-CoV-2 variant, increased. Circulation of other respiratory viruses followed usual historical patterns. Staying current with recommended RSV and COVID-19 vaccinations reduces the risk for severe illness and disease caused by these viruses.
Source: Morbidity and Mortality Weekly Report Journal, http://dx.doi.org/10.15585/mmwr.mm7545a2
____



















